We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Among those deemed “treatment sensitive,” 69.4% ...

Please provide your email address to receive an email when new articles are posted on . Monthly seizure frequency percentage reduction was 68.73% for the entire study cohort. For those followed up in ...

University of California San Diego is conducting new, Phase 2/3 national epilepsy clinical research trials, called Rise, to study BHV-7000, a novel investigational therapy, in focal epilepsy.

Most participants with newly diagnosed focal episodes achieve seizure freedom; 27% become seizure-free with first antiseizure medications. HealthDay News — Many people with newly diagnosed focal ...

HONG KONG – SK Biopharmaceuticals Co. Ltd. partner Arvelle Therapeutics GmbH, now part of Angelini Pharma, has received European Commission (EC) approval for Ontozry (cenobamate), a treatment for drug ...

Adding the novel drug XEN1101 to current antiseizure regimens significantly decreases seizures in patients with treatment-resistant focal epilepsy and can safely be taken at its highest dose, results ...

Valproate (Depakene) emerged as the best first-line choice for generalized epilepsy in a pragmatic study and lamotrigine (Lamictal) as the best first-line treatment for focal epilepsy, British ...

Continuous intracranial electroencephalography (cEEG) may help pinpoint optimal timing of diagnostic studies and treatment for patients with focal epilepsy, new research suggests. The findings from a ...

About one-third of patients with focal epilepsy, a common form of the neurological disorder, are believed to respond poorly to available therapies. Yet they, too, may eventually see improvement, if ...

CAMBRIDGE, Mass. & BARCELONA, Spain--(BUSINESS WIRE)--Neuroelectrics, a clinical-stage company pioneering brain stimulation therapies, has been granted FDA Breakthrough Device Designation for its ...